Eisai (4523) Aktienübersicht
Eisai Co., Ltd. ist in der Forschung und Entwicklung, der Herstellung, dem Verkauf sowie dem Import und Export von Arzneimitteln in Japan tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 4/6 |
4523 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 66.7% unterbewertet intrinsischer Abschlag
5419.8%Revenue growth p.a.
6.2k
18
0
126
Eisai Co., Ltd. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | JP¥4,687.00 |
| 52-Wochen-Hoch | JP¥5,349.00 |
| 52-Wochen-Tief | JP¥3,659.00 |
| Beta | -0.10 |
| 1 Monat Veränderung | -3.78% |
| 3 Monate Veränderung | 8.72% |
| 1 Jahr Veränderung | 12.91% |
| 3 Jahre Veränderung | -41.16% |
| 5 Jahre Veränderung | -34.93% |
| Veränderung seit IPO | 187.80% |
Aktuelle Nachrichten und Updates
4523: Future Alzheimer Dosing Approvals Will Still Not Justify Current Price
Analysts have adjusted their price target on Eisai to ¥3,674.94 from ¥3,600, reflecting updated assumptions around more measured revenue growth, a slightly lower profit margin, and a higher future P/E multiple. What's in the News Eisai and MSD submitted a Japanese application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and no new safety signals (Key Developments).
4523: Alzheimer’s Franchise And Oncology Pipeline Will Support Steady Long Term Outlook
Analysts have trimmed their Eisai price target slightly to ¥5,009 from ¥5,012, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What's in the News Eisai and MSD submitted a Japan application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 LITESPARK-011 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and a safety profile consistent with each monotherapy (Product-Related Announcements).Recent updates
4523: Future Alzheimer Dosing Approvals Will Still Not Justify Current Price
Analysts have adjusted their price target on Eisai to ¥3,674.94 from ¥3,600, reflecting updated assumptions around more measured revenue growth, a slightly lower profit margin, and a higher future P/E multiple. What's in the News Eisai and MSD submitted a Japanese application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and no new safety signals (Key Developments).4523: Alzheimer’s Franchise And Oncology Pipeline Will Support Steady Long Term Outlook
Analysts have trimmed their Eisai price target slightly to ¥5,009 from ¥5,012, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What's in the News Eisai and MSD submitted a Japan application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 LITESPARK-011 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and a safety profile consistent with each monotherapy (Product-Related Announcements).4523: Future Alzheimer Dosing Filings Will Still Not Support Current Valuation
Analysts have kept their ¥3,600 price target on Eisai steady, pointing to slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a lower assumed future P/E as the key drivers behind the updated view. What's in the News The U.S. FDA has granted Priority Review to Eisai's supplemental Biologics License Application for Leqembi Iqlik subcutaneous autoinjector as a weekly starting dose for early Alzheimer's disease, with a PDUFA action date set for May 24, 2026 (Key Developments).4523: Future Alzheimer Dosing Submissions Will Not Justify Current Share Price
Analysts have kept Eisai's fair value estimate steady at ¥3,600 per share. They cite updated assumptions for slightly higher revenue growth and profit margins, alongside a more conservative future P/E.
4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Margins And Future Share Returns
Analysts have kept their Eisai price target steady at ¥6,200. The latest update reflects slightly softer revenue growth expectations at 7.31%, a modestly higher profit margin outlook of 11.14%, and a small adjustment in assumed future P/E to 18.03x.Eisai's (TSE:4523) Shareholders Have More To Worry About Than Only Soft Earnings
Feb 17
Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Feb 11Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00
Feb 094523: Future Margin Upside From Subcutaneous Alzheimer’s Treatment Will Support Higher Returns
Analysts have lifted their fair value estimate for Eisai to ¥6,200 from ¥6,000, citing updated assumptions that combine a slightly higher discount rate and lower revenue growth with a stronger projected profit margin and a lower future P/E multiple. What's in the News Eisai and BioArctic submitted a Marketing Authorisation Variation to the European Medicines Agency for once every four weeks IV maintenance dosing of lecanemab, following an initial once every two weeks regimen for 18 months in early Alzheimer’s disease.Eisai's (TSE:4523) Dividend Will Be ¥80.00
Jan 264523: Long-Term Alzheimer Injection Shift Will Not Sustain Current Share Price
Analysts have kept Eisai's fair value estimate steady at ¥3,600.0, highlighting modest adjustments to revenue growth, profit margins and future P/E assumptions as they fine tune their price targets rather than rethink the core thesis. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous Leqembi autoinjector for early Alzheimer's treatment, with similar filings submitted to the U.S. FDA and Japan's PMDA, targeting at home weekly dosing as an alternative to current IV regimens (Key Developments).4523: Future Alzheimer Subcutaneous Rollout Will Not Support Current Share Price
Analysts have maintained their price target for Eisai at ¥3,600, citing updated assumptions for revenue growth, profit margins, and future P/E that continue to support the existing valuation framework. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous autoinjector formulation of Leqembi for early Alzheimer’s disease, with similar initiation dosing applications also submitted in the U.S. and Japan (Product related announcements) Eisai and partners reported clinical and modeling data at the CTAD conference suggesting long term lecanemab treatment was associated with delayed progression from mild cognitive impairment to more advanced Alzheimer’s stages, with subcutaneous dosing showing drug exposure comparable to intravenous administration (Product related announcements) Multiple filings were completed with the U.S. FDA for Leqembi Iqlik subcutaneous initiation dosing, following earlier approval for subcutaneous maintenance dosing.Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Jan 064523: Future Alzheimer Data Will Not Justify Current Share Price
Analysts have raised their price target on Eisai to 3,600.00, reflecting improved expectations for revenue growth and slightly stronger profit margins, despite a modest uptick in the assumed discount rate and a marginally lower future P/E multiple. What's in the News New long term data for Alzheimer therapy Leqembi suggest early and continued lecanemab treatment could delay progression from mild cognitive impairment to moderate Alzheimer disease by up to 8.3 years, which supports sustained use and earlier initiation (CTAD conference presentations).4523: Future Alzheimer’s Pipeline And At Home Treatments Will Support Steady Outlook
Analysts have slightly reduced their price target on Eisai, trimming fair value by about $15 per share to approximately $5,012. They cited marginally lower long term growth and profitability assumptions, while maintaining a similar forward earnings multiple.Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
Dec 034523: Upcoming Clinical Data And Regulatory Milestones Will Support Steady Long-Term Outlook
Analysts have maintained their price target for Eisai at ¥5,026.92, citing only minor adjustments to revenue growth and profit margin estimates. These adjustments did not significantly influence their overall valuation.Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Nov 19Eisai Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 094523: Upcoming Regulatory Approvals And Product Launches Will Drive Shares Higher
Narrative Update on Eisai: Analyst Price Target Revision Analysts have maintained their price target for Eisai at ¥5,026.92, citing slightly stronger revised revenue growth forecasts and a modest increase in the discount rate as underlying factors in their valuation assessment. What's in the News Health Canada issued a Notice of Compliance with conditions for LEQEMBI® (lecanemab), making it the first treatment for early Alzheimer's disease that targets an underlying cause to be authorized in Canada.Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects
Narrative Update on Eisai Analysts have raised Eisai’s price target modestly from ¥4,988 to ¥5,027. This change reflects slight improvements in revenue growth and profit margin assumptions.Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
Analysts have increased their price target for Eisai from ¥4,857.69 to ¥4,988.46. They cite slightly improved profit margin forecasts despite marginally lower expectations for revenue growth.Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Sep 22Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
The upward revision in the analyst price target for Eisai reflects a modest improvement in consensus revenue growth forecasts, now at 3.9% per annum, supporting the new fair value of ¥4858. What's in the News Eisai expanded its Canadian headquarters in Mississauga, increasing staff by 246% since 2020, demonstrating a firm commitment to R&D and healthcare innovation in Canada.Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00
Sep 08Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity
Eisai's consensus price target saw a marginal increase to ¥4,592, reflecting a slight improvement in revenue growth forecasts, while profit margins remained stable. What's in the News Eisai and Biogen launched LEQEMBI (lecanemab) in Austria and plan to launch in Germany, following EC approval as the first Alzheimer's disease therapy targeting both amyloid plaque and protofibrils, reducing clinical decline by 31% at 18 months versus placebo in the EU indicated population.Eisai's (TSE:4523) Dividend Will Be ¥80.00
Aug 25Eisai Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 08Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00
Jul 23Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Jul 09Eisai's (TSE:4523) Solid Profits Have Weak Fundamentals
Jun 22Here's What Analysts Are Forecasting For Eisai Co., Ltd. (TSE:4523) After Its Annual Results
May 18Aktionärsrenditen
| 4523 | JP Pharmaceuticals | JP Markt | |
|---|---|---|---|
| 7D | -1.1% | -4.0% | 0.6% |
| 1Y | 12.9% | 12.4% | 40.1% |
Rendite im Vergleich zur Industrie: 4523 wie die Branche JP Pharmaceuticals , die im vergangenen Jahr eine Rendite von 12.4 erzielte.
Rendite vs. Markt: 4523 hinter dem Markt JP zurück, der im vergangenen Jahr eine Rendite von 40.1 erzielte.
Preisvolatilität
| 4523 volatility | |
|---|---|
| 4523 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in JP Market | 9.5% |
| 10% least volatile stocks in JP Market | 2.4% |
Stabiler Aktienkurs: 4523 hatte in den letzten 3 Monaten im Vergleich zum JP -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 4523Die wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1941 | 10,917 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. beschäftigt sich mit der Forschung und Entwicklung, der Herstellung, dem Verkauf sowie dem Import und Export von Arzneimitteln in Japan. Das Unternehmen bietet Dayvigo zur Behandlung von Schlaflosigkeit, Lenvima, ein Antikrebsmittel/molekulares zielgerichtetes Medikament zur Behandlung von Schilddrüsenkrebs, Nierenzellkarzinom in Kombination mit Everolimus und hepatozellulärem Karzinom, Methycobal zur Behandlung von peripherer Neuropathie und Halaven, ein Antikrebsmittel zur Behandlung von Brustkrebs. Das Unternehmen bietet auch Jyseleca, einen Januskinase-Hemmer, Elental, ein Präparat mit verzweigtkettigen Aminosäuren, Goofice und Movicol für chronische Verstopfung, Fycompa, ein Antiepileptikum, Pariet, einen Protonenpumpenhemmer, Aricept für die Alzheimer-Krankheit/Demenz mit Lewy-Körpern, und Chocola BB plus für das Präparat Vitamin B2.
Eisai Co., Ltd.'s Grundlagenzusammenfassung
| 4523 grundlegende Statistiken | |
|---|---|
| Marktanteil | JP¥1.32t |
| Gewinn(TTM) | JP¥42.76b |
| Umsatz(TTM) | JP¥808.19b |
30.9x
Kurs-Gewinn-Verhältnis 1.6x
Kurs-Umsatz-VerhältnisIst 4523 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 4523 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | JP¥808.19b |
| Kosten der Einnahmen | JP¥179.81b |
| Bruttogewinn | JP¥628.38b |
| Sonstige Ausgaben | JP¥585.62b |
| Gewinn | JP¥42.76b |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
May 15, 2026
| Gewinn per Aktie (EPS) | 151.68 |
| Bruttomarge | 77.75% |
| Nettogewinnspanne | 5.29% |
| Schulden/Eigenkapital-Verhältnis | 25.2% |
Wie hat sich 4523 auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
3.4%
Aktuelle Dividendenrendite106%
AusschüttungsquoteZahlt 4523 eine zuverlässige Dividende?
Siehe 4523 Dividendenhistorie und Benchmarks| Eisai Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Mar 30 2026 |
| Datum der Dividendenzahlung | Jun 01 2026 |
| Tage bis Ex-Dividende | 32 days |
| Tage bis zum Datum der Dividendenzahlung | 31 days |
Zahlt 4523 eine zuverlässige Dividende?
Siehe 4523 Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/04/30 17:16 |
| Aktienkurs zum Tagesende | 2026/04/30 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Eisai Co., Ltd. wird von 21 Analysten beobachtet. 13 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |